The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II multi-cohort single-arm study of tiragolumab with atezolizumab plus bevacizumab in previously treated advanced non-squamous non–small-cell lung cancer.
 
Joshua E. Reuss
Honoraria - AstraZeneca/MedImmune; Merck
Consulting or Advisory Role - Arcus Biosciences; AstraZeneca; Bristol-Myers Squibb; Genentech/Roche; Guardant Health; Personalis; Sanofi
Research Funding - Genentech/Roche (Inst); Nuvalent, Inc. (Inst); Verastem (Inst)
 
Dann Wonser
No Relationships to Disclose
 
Kellie Nicole Smith
Stock and Other Ownership Interests - ManaT Bio
Honoraria - Adaptive Biotechnologies
Consulting or Advisory Role - Adaptive Biotechnologies
 
Jaeil Ahn
Consulting or Advisory Role - KeifeRx; KeifeRx
 
Stephen Byers
No Relationships to Disclose
 
Karen Creswell
No Relationships to Disclose
 
Chul Kim
Consulting or Advisory Role - Arcus Biosciences; AstraZeneca; Daiichi Sankyo; Diffusion Pharmaceuticals; Eisai; Janssen; Jazz Pharmaceuticals; Mirati Therapeutics; Novartis; PierianDx; Sanofi
Research Funding - AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; Debiopharm Group; Genentech/Roche; Janssen; Karyopharm Therapeutics; Novartis; Regeneron
 
Jillian Thompson
No Relationships to Disclose
 
Jenny Crawford
No Relationships to Disclose
 
Emil Cohen
No Relationships to Disclose
 
Jay Zeck
No Relationships to Disclose
 
Martin Gutierrez
Stock and Other Ownership Interests - Cota Healthcare
Speakers' Bureau - BMS; Lilly; Merck
Research Funding - Acerta Pharma (Inst); Adlai Nortye (Inst); Arcus Biosciences (Inst); Array BioPharma (Inst); Bayer (Inst); Bellicum Pharmaceuticals (Inst); BMS (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); Checkpoint Therapeutics (Inst); Compass Therapeutics (Inst); Constellation Pharmaceuticals (Inst); Cullinan Oncology (Inst); Cyteir (Inst); Daiichi Sankyo Company (Inst); Eisai (Inst); EMD Serono (Inst); EMD Serono (Inst); Erasca, Inc (Inst); Fate Therapeutics (Inst); Georgetown Univ. (Inst); GlaxoSmithKline (Inst); GSB Pharma (Inst); Hackensack Meridian Health (Inst); Imugene (Inst); Incyte (Inst); Incyte (Inst); Infinity Pharmaceuticals (Inst); ITeos Therapeutics (Inst); Janssen (Inst); Johnson & Johnson (Inst); KSQ Therapeutics (Inst); MedImmune (Inst); Memorial Sloan-Kettering Cancer Center (Inst); Merck (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Moderna Therapeutics (Inst); NextCure (Inst); NextCure (Inst); Nimbus Therapeutics (Inst); Pfizer (Inst); Pharmacyclics (Inst); Rapa Therapeutics (Inst); Regeneron (Inst); Roche/Genentech (Inst); Sanofi (Inst); Seagen (Inst); Silenseed (Inst); Silenseed (Inst); Synlogic (Inst); Tesaro (Inst); Turning Point Therapeutics (Inst); Vedanta Biosciences (Inst); VelosBio (Inst); Verastem (Inst); Vincerx Pharma (Inst)
Travel, Accommodations, Expenses - Guardant Health
 
Stephen V. Liu
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Candel Therapeutics; Catalyst Pharmaceuticals; Daiichi Sankyo/UCB Japan; Eisai; Elevation Oncology; Genentech; Gilead Sciences; Guardant Health; Janssen Oncology; Jazz Pharmaceuticals; Merus; MSD Oncology; Novartis; Regeneron; Sanofi; Takeda; Turning Point Therapeutics
Research Funding - Alkermes (Inst); Elevation Oncology (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Merck (Inst); Merus (Inst); Nuvalent, Inc. (Inst); RAPT Therapeutics (Inst); Turning Point Therapeutics (Inst)
Travel, Accommodations, Expenses - Caris Life Sciences